Trial reportSignal transduction and targeted therapy2021
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.
3 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 175 papers, 25 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
175citing papers in PubMed, 25 pooled it
60.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19
MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury
NCT06492798 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation
Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients
Who cites it
175 citing papers in PubMed, 25 syntheses or guidelines pooled it, 306 citations in OpenAlex.
- Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis.Stem cells translational medicine · 2026Pooled it
- Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset.Stem cell research & therapy · 2026Pooled it
- Therapeutic potential of dental mesenchymal stem cells versus mesenchymal stem cells from other sources: a systematic review of animal studies.BMC oral health · 2025Pooled it
- Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis.Stem cell research & therapy · 2025Pooled it
- Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Journal of translational medicine · 2024Pooled it
- Stem Cell Extracellular Vesicles as Anti-SARS-CoV-2 Immunomodulatory Therapeutics: A Systematic Review of Clinical and Preclinical Studies.Stem cell reviews and reports · 2024Pooled it
- Mesenchymal Stem Cells on Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Stem cell reviews and reports · 2024Pooled it
- Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis.Immunity, inflammation and disease · 2023Pooled it
- Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials.Stem cell research & therapy · 2023Pooled it
- Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?Cytotherapy · 2023Pooled it
- The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials.Critical care (London, England) · 2023Pooled it
- Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.Frontiers in immunology · 2023Pooled it
- Efficacy and Safety of Mesenchymal Stromal Cells Therapy for COVID-19 Infection: A Systematic Review and Meta-analysis.Current stem cell research & therapy · 2023Pooled it
- The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.Journal of infection and public health · 2022Pooled it
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.Stem cells translational medicine · 2022Pooled it
- Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval.Stem cells translational medicine · 2022Pooled it
- Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis.Global health research and policy · 2022Pooled it
- Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends.BioMed research international · 2022Pooled it
- Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.Frontiers in immunology · 2022Pooled it
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 7 institutions in 4 countries.
Lei Shi *Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Hai Huang *Department of Respiratory, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Xuechun Lu *Wuhan Huoshenshan Hospital, Wuhan, China.
Xiaoyan Yan *Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China.
Xiaojing JiangDepartment of Infectious Disease, General Hospital of Central Theater Command, Wuhan, China.
Ruonan XuDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Siyu WangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Chao ZhangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.ORCID 0000-0001-8126-8145
Xin YuanDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Zhe XuDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Lei HuangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Jun-Liang FuDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Yuanyuan LiDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Yu ZhangVCANBIO Cell & Gene Engineering Corp., Ltd, Tianjin, China.
Wei-Qi YaoNational Industrial Base for Stem Cell Engineering Products, Tianjin, China.
Tianyi LiuWuhan Huoshenshan Hospital, Wuhan, China.
Jinwen SongDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.ORCID 0000-0002-8582-8012
Liangliang SunOptical Valley Branch of Maternal and Child Hospital of Hubei Province, Wuhan, China.
Fan YangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xin ZhangWuhan Huoshenshan Hospital, Wuhan, China.
Bo ZhangDepartment of Infectious Disease, General Hospital of Central Theater Command, Wuhan, China.
Ming ShiDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Fanping MengDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Yanning SongDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
Yongpei YuPeking University Clinical Research Institute, Peking University First Hospital, Beijing, China.
Jiqiu WenWuhan Huoshenshan Hospital, Wuhan, China.
Qi LiWuhan Huoshenshan Hospital, Wuhan, China.
Qing MaoWuhan Huoshenshan Hospital, Wuhan, China.
Markus MaeurerImmunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal.
Alimuddin ZumlaCenter for Clinical Microbiology, Division of Infection and Immunity, University College London, and UCL Hospitals NIHR Biomedical Research Centre, London, UK.
Chen YaoPeking University Clinical Research Institute, Peking University First Hospital, Beijing, China. yaochen@hsc.pku.edu.cn.
Wei-Fen XieOptical Valley Branch of Maternal and Child Hospital of Hubei Province, Wuhan, China. weifenxie@medmail.com.cn.
Fu-Sheng WangDepartment of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. fswang302@163.com.ORCID 0000-0002-8043-6685
Chinese PLA General Hospital · CNPeking University · CNSecond Military Medical University · CNGeneral Hospital of Central Theater CommandUnion Hospital · CNChampalimaud Foundation · PTUCL Biomedical Research Centre · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of severe Coronavirus Disease 2019 (COVID-19) is challenging. We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data. In this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe COVID-19 patients with lung damage. They were randomly assigned at a 2:1 ratio to receive either UC-MSCs (4 × 10
Indexed as
Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationSARS-CoV-2Umbilical CordAgedAllograftsCOVID-19Double-Blind MethodFemaleHumansMaleMiddle AgedTreatment Outcome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.